Adia Med Explores International Expansion Following Global Interest in Its Innovative Umbilical Cord Blood Stem Cell Therapies
Adia Nutrition (OTC Pink: ADIA) announces global expansion plans for its subsidiary Adia Med following strong international interest. The company has received multiple inquiries from healthcare organizations worldwide interested in establishing clinics offering their advanced treatments.
Key developments include:
- Legal clearance received for international expansion
- Specific location identified outside the US for first international clinic
- Focus on cutting-edge treatments including Therapeutic Plasma Exchange, Hematopoietic Stem Cell Transplantation, and umbilical cord blood stem cell therapies
- Featuring their premier product Adia Vita, known for high potency and purity in regenerative medicine
Adia Med stands as one of only three clinic networks in the US with specialized technology for these treatments. CEO Larry Powalisz confirms they are actively pursuing international opportunities while ensuring compliance with global healthcare standards. The expansion aims to bring their innovative therapies, particularly the sought-after Adia Vita treatment, to patients worldwide.
Adia Nutrition (OTC Pink: ADIA) annuncia piani di espansione globale per la sua controllata Adia Med a seguito di un forte interesse internazionale. L'azienda ha ricevuto numerose richieste da parte di organizzazioni sanitarie in tutto il mondo interessate ad aprire cliniche che offrano i loro trattamenti avanzati.
Sviluppi chiave includono:
- Ottenuta l'autorizzazione legale per l'espansione internazionale
- Individuato un sito specifico al di fuori degli Stati Uniti per la prima clinica internazionale
- Focus su trattamenti all'avanguardia come Scambio Plasmatico Terapeutico, Trapianto di Cellule Staminali Ematopoietiche e terapie con cellule staminali del sangue del cordone ombelicale
- Presentazione del prodotto di punta Adia Vita, noto per l'alta potenza e purezza nella medicina rigenerativa
Adia Med è una delle sole tre reti di cliniche negli Stati Uniti dotate di tecnologia specializzata per questi trattamenti. Il CEO Larry Powalisz conferma che stanno attivamente perseguendo opportunità internazionali garantendo al contempo la conformità agli standard sanitari globali. L'espansione mira a portare le loro terapie innovative, in particolare il ricercato trattamento Adia Vita, ai pazienti di tutto il mondo.
Adia Nutrition (OTC Pink: ADIA) anuncia planes de expansión global para su subsidiaria Adia Med tras un fuerte interés internacional. La compañía ha recibido múltiples consultas de organizaciones sanitarias en todo el mundo interesadas en establecer clínicas que ofrezcan sus tratamientos avanzados.
Desarrollos clave incluyen:
- Aprobación legal obtenida para la expansión internacional
- Ubicación específica identificada fuera de EE.UU. para la primera clínica internacional
- Enfoque en tratamientos de vanguardia como Intercambio Terapéutico de Plasma, Trasplante de Células Madre Hematopoyéticas y terapias con células madre de sangre de cordón umbilical
- Presentación de su producto principal Adia Vita, reconocido por su alta potencia y pureza en medicina regenerativa
Adia Med es una de las tres únicas redes de clínicas en EE.UU. con tecnología especializada para estos tratamientos. El CEO Larry Powalisz confirma que están buscando activamente oportunidades internacionales mientras aseguran el cumplimiento de los estándares sanitarios globales. La expansión tiene como objetivo llevar sus terapias innovadoras, especialmente el muy solicitado tratamiento Adia Vita, a pacientes de todo el mundo.
Adia Nutrition (OTC Pink: ADIA)는 자회사 Adia Med의 글로벌 확장 계획을 강력한 국제적 관심에 힘입어 발표했습니다. 회사는 전 세계 의료 기관들로부터 첨단 치료법을 제공하는 클리닉 설립에 관한 다수의 문의를 받았습니다.
주요 발전 사항은 다음과 같습니다:
- 국제 확장을 위한 법적 승인 획득
- 미국 외 첫 국제 클리닉을 위한 구체적인 위치 선정
- 치료용 혈장 교환, 조혈모세포 이식, 탯줄 혈액 줄기세포 치료 등 첨단 치료에 집중
- 재생 의학에서 높은 효능과 순도를 자랑하는 대표 제품 Adia Vita 선보임
Adia Med는 미국 내 이 치료법에 특화된 기술을 보유한 세 개의 클리닉 네트워크 중 하나입니다. CEO Larry Powalisz는 국제 기회를 적극 모색하는 동시에 글로벌 의료 기준 준수를 보장하고 있다고 밝혔습니다. 이번 확장은 특히 인기 있는 Adia Vita 치료를 전 세계 환자들에게 제공하는 것을 목표로 합니다.
Adia Nutrition (OTC Pink : ADIA) annonce des plans d'expansion mondiale pour sa filiale Adia Med suite à un fort intérêt international. L'entreprise a reçu de nombreuses demandes de la part d'organisations de santé à travers le monde souhaitant établir des cliniques proposant leurs traitements avancés.
Principaux développements :
- Approbation légale obtenue pour l'expansion internationale
- Emplacement spécifique identifié en dehors des États-Unis pour la première clinique internationale
- Focus sur des traitements de pointe incluant l'échange thérapeutique de plasma, la transplantation de cellules souches hématopoïétiques et les thérapies par cellules souches du sang de cordon ombilical
- Mise en avant de leur produit phare Adia Vita, reconnu pour sa haute puissance et pureté en médecine régénérative
Adia Med est l'un des trois seuls réseaux de cliniques aux États-Unis disposant d'une technologie spécialisée pour ces traitements. Le PDG Larry Powalisz confirme qu'ils poursuivent activement des opportunités internationales tout en assurant le respect des normes sanitaires mondiales. L'expansion vise à offrir leurs thérapies innovantes, en particulier le traitement très demandé Adia Vita, aux patients du monde entier.
Adia Nutrition (OTC Pink: ADIA) kündigt globale Expansionspläne für seine Tochtergesellschaft Adia Med nach starkem internationalem Interesse an. Das Unternehmen hat zahlreiche Anfragen von Gesundheitsorganisationen weltweit erhalten, die daran interessiert sind, Kliniken mit deren fortschrittlichen Behandlungen einzurichten.
Wichtige Entwicklungen umfassen:
- Rechtliche Genehmigung für internationale Expansion erhalten
- Spezifischer Standort außerhalb der USA für die erste internationale Klinik identifiziert
- Fokus auf hochmoderne Behandlungen wie Therapeutischer Plasmataustausch, Hämatopoetische Stammzelltransplantation und Nabelschnurblut-Stammzelltherapien
- Präsentation ihres Spitzenprodukts Adia Vita, bekannt für hohe Wirksamkeit und Reinheit in der regenerativen Medizin
Adia Med ist eines von nur drei Kliniknetzwerken in den USA mit spezialisierter Technologie für diese Behandlungen. CEO Larry Powalisz bestätigt, dass sie aktiv internationale Möglichkeiten verfolgen und gleichzeitig die Einhaltung globaler Gesundheitsstandards gewährleisten. Die Expansion zielt darauf ab, ihre innovativen Therapien, insbesondere die gefragte Adia Vita-Behandlung, weltweit für Patienten verfügbar zu machen.
- Global expansion potential with multiple international organizations expressing interest in Adia Med's treatments
- Legal clearance received for international operations, confirming feasibility of global expansion
- Specific international location already identified for first expansion
- Company offers unique treatments including TPE and HSCT, being one of only three clinic networks in US with this technology
- Strong market positioning with proprietary Adia Vita product gaining international recognition
- International expansion still in early planning phase without concrete timeline
- Regulatory requirements and compliance costs for international operations not yet determined
- No specific financial metrics or investment requirements disclosed for expansion plans
Winter Park, Florida--(Newsfile Corp. - March 25, 2025) - Adia Nutrition (OTC Pink: ADIA), a trailblazer in advanced healthcare solutions, is excited to announce that its subsidiary, Adia Med, is actively exploring international expansion after receiving significant interest from multiple international groups. Over recent months, several organizations and healthcare entities from various countries have reached out to Adia Med, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including Therapeutic Plasma Exchange (TPE), Hematopoietic Stem Cell Transplantation (HSCT), and notably, umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. In response, Adia Med has begun a comprehensive review of the legalities and regulations required to bring its pioneering care to a global stage.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/243471__bf477173-b44d-457c-bb35-7984f21e1815.jpg
Adia Med's leadership has taken proactive steps toward this potential expansion, consulting legal experts to evaluate the feasibility of operating clinics abroad. The company recently received a letter of opinion from its legal counsel, confirming that international expansion is permissible and providing a detailed blueprint for navigating the regulatory landscape. This legal framework outlines the steps needed to comply with international healthcare standards, setting the stage for Adia Med to extend its innovative therapies, including the highly sought-after Adia Vita, beyond the United States.
"We've been overwhelmed by the global enthusiasm for our work, particularly from groups interested in leveraging Adia Labs' Adia Vita for umbilical cord blood stem cell therapies," said Larry Powalisz, CEO of Adia Med. "Our current location is already delivering transformative treatments, and with this international outreach, we're exploring how to share our advancements, like Adia Vita, our premier stem cell product, with the world. We've already identified an appealing location outside the U.S. that we're likely to pursue, and our lawyer's guidance assures us that going international is within reach."
Adia Vita, offered by Adia Labs, has garnered attention for its unprecedented potency and purity, making it a standout in regenerative medicine. International groups have expressed keen interest in utilizing this premier UCB-SC product for therapies targeting a range of conditions, from circulatory disorders to orthopedic applications. Adia Med's expertise with apheresis machines for TPE and HSCT, combined with its leadership in UCB-SC therapies, positions it as one of only three clinic networks in the U.S. with this technology—a distinction that has fueled global curiosity.
While the expansion remains in the planning phase, Adia Med is committed to meeting this international demand by carefully assessing regulatory requirements, forging strategic partnerships, and refining its approach to ensure a smooth entry into new markets. Larry Powalisz, CEO of Adia Nutrition, shared, "We've recently pinpointed a specific location outside the US for launching our first international Adia Med," signaling a clear step toward global outreach. This move aligns with Adia Nutrition's mission to revolutionize healthcare and deliver impactful solutions worldwide, leveraging their expertise in regenerative medicine to reach new patients beyond U.S. borders.
For more information about Adia Med's current offerings, including Adia Vita, or updates on its international plans, please visit www.adiamed.com or contact ceo@adiamed.com.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243471
FAQ
What international expansion plans does Adia Nutrition (ADIA) announce in March 2025?
What treatments does Adia Med (ADIA) offer in its clinics?
How is Adia Med (ADIA) preparing for its global expansion in 2025?
What makes Adia Med's (ADIA) stem cell product Adia Vita unique?
What competitive advantage does Adia Med (ADIA) have in the US market?
